Friday, July 10, 2026

Drug profile · INN

axicabtagene ciloleucel

axicabtagene ciloleucel (YESCARTA) is a b-lymphocyte antigen cd19 binding agent.

EMA: approved Antineoplastic and immunomodulating agents (L01) L01XX70
Patents linked 0
Pipeline programs 4
News articles 6
Drug details — axicabtagene ciloleucel

Quick answer

axicabtagene ciloleucel (YESCARTA) is a b-lymphocyte antigen cd19 binding agent.

Key facts

INN axicabtagene ciloleucel
Brand YESCARTA
Mechanism B-lymphocyte antigen CD19 binding agent
Target B-lymphocyte antigen CD19
Therapeutic class Antineoplastic and immunomodulating agents (L01)
ATC code L01XX70

Mechanism of action

B-lymphocyte antigen CD19 binding agent

Primary target: B-lymphocyte antigen CD19

Approval history

Authority Status Date
EMA approved

Recent coverage

Pipeline programs

  1. KT-US-473-0133 Phase 3 · Anaxis Pharma · Relapsed/Refractory Follicular Lymphoma
  2. HO161 Phase 2 · Disc Medicine · relapsed/refractory Non-Hodgkin Lymphoma
  3. KT-US-982-5968 Phase 2 · Anaxis Pharma · Solid and Hematological Malignancies
  4. UKD-IKF-Double-T Phase 2 · George Institute for · relapsed/refractory Large B-Cell Lymphoma

Related & competitor drugs

  1. abiraterone acetate Antineoplastic and immunomodulating agents (L02)
  2. anagrelide Antineoplastic and immunomodulating agents (L01)
  3. apremilast Antineoplastic and immunomodulating agents (L04)
  4. arsenic trioxide Antineoplastic and immunomodulating agents (L01)
  5. axitinib Antineoplastic and immunomodulating agents (L01)
  6. azacitidine Antineoplastic and immunomodulating agents (L01)

Frequently asked questions

What is axicabtagene ciloleucel?

axicabtagene ciloleucel (YESCARTA) is a b-lymphocyte antigen cd19 binding agent.

What is the brand name for axicabtagene ciloleucel?

YESCARTA is a marketed brand name for axicabtagene ciloleucel. Check FDA Drugs@FDA for the current US label holder and prescribing information.